It’s been said before and it’s true: a healthy scalp is key to healthy hair. But for those dealing with pesky and sometimes painful scalp conditions like seborrheic dermatitis, that can be easier said ...
WESTLAKE VILLAGE, Calif., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...
ZORYVE foam 0.3% was safe, well-tolerated, and demonstrated durable and continuously improving efficacy in the treatment of seborrheic dermatitis up to 52 weeks Once-daily ZORYVE foam 0.3% is approved ...
Please provide your email address to receive an email when new articles are posted on . Seborrheic dermatitis is often treated with topical antifungals or corticosteroids, which can be cumbersome on ...
Credit: Arcutis. Zoryve topical foam is a once-daily steroid-free formulation of a highly potent and selective phosphodiesterase type 4 inhibitor. The Food and Drug Administration (FDA) has approved ...
Please provide your email address to receive an email when new articles are posted on . The FDA will review a new drug application for roflumilast foam 0.3% to treat seborrheic dermatitis in patients ...
Dear Dr. Gott: My husband has been diagnosed with seborrheic dermatitis. Medication has been ineffective. We have been using Neosporin and antiseptic powder on the open areas and aloe vera on his ...
TORONTO, Oct. 21, 2024 /CNW/ - Arcutis Canada Inc., a commercial-stage company focused on delivering meaningful innovations in immuno-dermatology, is pleased to announce that Health Canada has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback